Insights on Ingrezza for Tardive Dyskinesia

Ingrezza, whose active ingredient is valbenazine, is an FDA approved medicine for adults with tardive dyskinesia. Tardive dyskinesia can cause persistent, involuntary movements involving the face, mouth, tongue, limbs, or other parts of the body. It may develop after exposure to certain medicines that affect dopamine signaling. Ingrezza is classified as a vesicular monoamine transporter 2 inhibitor and is thought to reduce abnormal dopamine signaling associated with these movements.

Understanding Ingrezza for Tardive Dyskinesia

Ingrezza is designed to help reduce the involuntary movements associated with tardive dyskinesia. Clinical research has evaluated changes in symptoms using the Abnormal Involuntary Movement Scale, or AIMS. In a six week clinical trial, adults receiving the recommended 80 mg dose showed a greater average improvement in AIMS scores than those receiving placebo. Individual responses can vary, and treatment decisions should be made with a qualified healthcare professional.

Important points about Ingrezza include:

• The active ingredient is valbenazine.
• It is approved for adults with tardive dyskinesia.
• It is taken orally once daily and may be taken with or without food.
• The FDA labeling lists 40 mg once daily as the initial dose for tardive dyskinesia, followed after one week by the recommended 80 mg once daily dose.
• Depending on response, tolerability, or certain patient factors, a healthcare professional may consider a lower daily dose.
• The medicine should be taken according to the prescribed instructions rather than adjusted independently.

Ingrezza does not mean that a person should automatically stop the medication that may have contributed to tardive dyskinesia. Changes to antipsychotic or other prescribed medicines should be discussed with the treating healthcare professional.

Safety Considerations and Treatment Monitoring

Like other prescription medicines, Ingrezza can cause side effects and may not be appropriate for everyone. The FDA prescribing information identifies somnolence or sleepiness as a common adverse reaction in people treated for tardive dyskinesia. It also includes warnings concerning hypersensitivity reactions, QT interval prolongation, neuroleptic malignant syndrome, and parkinsonism. Healthcare professionals may consider a person's medical history and other medicines when determining whether Ingrezza is appropriate.

Safety considerations include:

• Sleepiness or sedation can occur and may affect activities requiring alertness.
• Ingrezza can interact with medicines that affect CYP3A4 or CYP2D6 enzymes, which may require dose adjustment.
• Concomitant use with monoamine oxidase inhibitors should be avoided according to the FDA labeling.
• People with certain heart rhythm conditions may require particular caution because of potential QT interval prolongation.
• New or worsening parkinson-like symptoms should be reported to a healthcare professional.
• Allergic reactions, including angioedema, require prompt medical attention.
• Pregnancy and breastfeeding require discussion with a healthcare professional because the FDA labeling includes specific precautions.

Ingrezza is a treatment option that should be considered as part of an individualized approach to tardive dyskinesia. A healthcare professional can assess symptoms, medication history, other health conditions, and potential interactions before recommending treatment. General information about Ingrezza can support informed discussions, but it should not be used to diagnose tardive dyskinesia or determine a personal dose.

Ingrezza, or valbenazine, is an FDA approved VMAT2 inhibitor for treating tardive dyskinesia in adults. It may reduce involuntary movements associated with the condition, while its safety profile and dosing requirements should be considered for each individual. Understanding how the medicine works, its approved dosing, potential interactions, and important safety considerations can help patients have informed conversations with their healthcare professionals. This information is educational only and is not intended as medical advice, sales information, or a substitute for professional care.